TerminatedNCT03261817
Official study titleClinical and Brain Effects of Remote Web-based Adapted Physical Activity (e-APA) in Patients With Psychotic Disorders and Healthy Subjects: A Controlled, Multicenter Study
This study ended early.
Remote / onlineSchizophreniaBehavioural studyAges 18–60
- Countries
- France
- Sponsor
- University Hospital, Caen
CompletedEUCTR 2008-006492-71
This study has finished and is no longer accepting participants.
Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.
In FranceDepressionHistorical research record
- Countries
- France, Estonia, Finland, + 2 others
- Sponsor
- Eli Lilly and Company
CompletedEUCTR 2009-016667-11
This study has finished and is no longer accepting participants.
Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.
In FranceBipolarity, DepressionHistorical research record
- Countries
- France, Bulgaria, Spain
- Sponsor
- Cephalon, Inc.
CompletedEUCTR 2008-001673-15
This study has finished and is no longer accepting participants.
Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.
In FranceAnxietyHistorical research record
- Countries
- France, Estonia, Finland, + 1 other
- Sponsor
- H. Lundbeck A/S
CompletedNCT00700427
Official study titleMaintenance of Response After Open-Label Treatment With Atomoxetine Hydrochloride in Adult Outpatients With Attention-Deficit/Hyperactivity Disorder (ADHD): A Placebo-Controlled, Randomized Withdrawal Study
This study has finished and is no longer accepting participants.
In FranceADHDMedication studyAges 18–50
- Countries
- France, United Kingdom, Switzerland, + 9 others
- Sponsor
- Eli Lilly and Company
CompletedNCT02782104
What is this study about?This study evaluated the safety of Esketamine Nasal Spray for people with depression.
This study has finished and is no longer accepting participants.
In FranceDepressionMedication studyAges 18+
- Countries
- France, United States, Australia, + 23 others
- Sponsor
- Janssen Research & Development, LLC
TerminatedNCT01487083
What is this study about?Researchers are studying Pomaglumetad methionil, tracking side effects to assess long-term safety in people with schizophrenia.
This study ended early.
In FranceSchizophreniaMedication studyAges 18–65
- Countries
- France, United States, Austria, + 7 others
- Sponsor
- Denovo Biopharma LLC
CompletedNCT02497287
Official study titleAn Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression
This study has finished and is no longer accepting participants.
In FranceDepressionMedication studyAges 18+
- Countries
- France, United States, Australia, + 18 others
- Sponsor
- Janssen Research & Development, LLC
CompletedEUCTR 2007-003035-22
This study has finished and is no longer accepting participants.
Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.
In FranceSchizophreniaHistorical research record
- Countries
- France, United Kingdom, Belgium, + 4 others
- Sponsor
- ACADIA Pharmaceuticals Inc.
CompletedEUCTR 2015-005282-22
This study has finished and is no longer accepting participants.
Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.
In FranceDepressionHistorical research record
- Countries
- France, Bulgaria, Finland, + 1 other
- Sponsor
- Janssen-Cilag International NV
CompletedEUCTR 2007-002111-82
This study has finished and is no longer accepting participants.
Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.
In FranceADHDHistorical research record
- Countries
- France, United Kingdom, Belgium, + 6 others
- Sponsor
- Janssen-Cilag International N.V., Turnhoutseweg 30, B-2340 Beerse, Belgium
CompletedNCT01959659
What is this study about?This completed observational study examined healthcare use and the impact of persistent schizophrenia symptoms despite adequately dosed antipsychotic treatment.
This study has finished and is no longer accepting participants.
In FranceSchizophreniaObservational studyAges 18+
- Countries
- France, Australia, Czechia, + 4 others
- Sponsor
- Hoffmann-La Roche